Altimmune, Inc. (ALT) News
Track canonical SquawkNews coverage tagged to ALT, Altimmune, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Altimmune Price Target Cut to $17.00/Share From $18.00 by Evercore ISI Group
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 01:22 PM UTC
L
Altimmune to Participate in Stifel Cardiometabolic Forum
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. NASDAQ:ALT, a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management
NEWS | Sep 23, 2026, 12:01 PM UTC
L
ALT - Altimmune to Participate in Stifel Cardiometabolic Forum
ALT - Altimmune to Participate in Stifel Cardiometabolic Forum
NEWS | Sep 23, 2026, 12:01 PM UTC
M
VKTX, GPCR, ALT stocks jump after Novo Nordisk M&A signal
Novo Nordisk said it could pursue larger acquisitions while targeting more than five “multi-blockbuster” launches by 2030, lifting smaller obesity players: Viking Therapeutics gained nearly 4%, Structure Therapeutics ros
EQUITY | Sep 22, 2026, 05:29 AM UTC
L
ALT: Pemvidutide advances in late-stage liver disease trials, emphasizing dual action and strong tolerability
Management outlined progress in late-stage liver disease trials, highlighting pemvidutide's dual mechanism, strong phase II data in MASH and AUD, and robust financials supporting execution. Key differentiators include to
FX | Sep 10, 2026, 02:55 PM UTC
L
ALT: Phase III MASH trial enrollment advances, with strong data and financials supporting broad liver disease focus
Management highlighted late-stage progress for pemvidutide in liver diseases, with phase III MASH enrollment underway and strong phase II results in AUD and ALD. Differentiation is driven by dual liver and metabolic acti
FX | Sep 10, 2026, 02:26 PM UTC
L
Altimmune to participate in Wells Fargo 21st Annual Healthcare conference fireside chat
Altimmune announced management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
ALT - Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
ALT - Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
EQUITY | Sep 03, 2026, 12:01 PM UTC
L
Alt Reports Wider Loss
Alt reports net loss of $22.8M, wider than $22.1M YoY
EARNINGS | Aug 12, 2026, 11:34 AM UTC
L
ALT Reports Q2 2026 Financial Results
Altimmune announces second quarter 2026 financial results and business update
EARNINGS | Aug 12, 2026, 11:30 AM UTC
L
ALT - Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
ALT - Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
EARNINGS | Aug 05, 2026, 12:01 PM UTC
M
Altimmune Initiates Pemvidutide Phase 3 Trial
Altimmune starts Phase 3 trial for Pemvidutide
EQUITY | Aug 03, 2026, 12:01 PM UTC
L
ALT gives up premarket gains of over 20% on drug headlines earlier; shares flat
ALT gives up premarket gains of over 20% on drug headlines earlier; shares flat
EQUITY | Jul 28, 2026, 02:18 PM UTC
L
ALT +18% premarket after trial headlines
ALT +18% premarket after trial headlines
EQUITY | Jul 28, 2026, 11:08 AM UTC
L
Watching Altimmune; Shares Move Higher, Traders Circulate Stock Picked By Popular Retail Traders Newsletter
Watching Altimmune; Shares Move Higher, Traders Circulate Stock Picked By Popular Retail Traders Newsletter
EQUITY | Jul 01, 2026, 02:57 PM UTC
M
ALT: Leerink Initiates
Leerink Partners initiates coverage on Altimmune with an Outperform rating and a price target of $10
EQUITY | Jun 22, 2026, 02:45 PM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 22, 2026, 10:57 AM UTC